VILLEJUIF, France--(BUSINESS WIRE)--“We are very proud to welcome Institut Curie to WIN,” said Dr. John
Mendelsohn, Chairman of WIN and Director of the Khalifa Institute for
Personalized Cancer Therapy and past President of MD Anderson Cancer
Center. “The Institut Curie is undeniably a leading European cancer
research center with remarkable research that will constitute a major
asset for WIN.”
WIN’s mission is to rapidly translate precision
cancer medicine discoveries into standards of patient care worldwide.
“Our vision and value proposition is that we can accomplish more
together than each organization can achieve working alone. In WIN,
renown academics and industries work hand in hand to develop the tools
and therapies needed to significantly improve survival and quality of
life of cancer patients from diverse backgrounds.” said Dr. Vladimir
Lazar, Chief Operating Officer of WIN. WIN, through its network of academics,
industries, insurance and patient advocates, is present in 14 countries
and 4 continents. Not only it provides an effective platform to launch
clinical trials but it is the place where transformational proof of
concept trials paving the way for the future of cancer care can be
developed, such as WINTHER, first trial of the WIN Consortium which was
selected as a Success Story of the EUFP7.
WIN enables
simultaneous access to patients with varied genetic backgrounds,
enhancing the speed and efficacy with which novel discoveries can be
made, in particular new biomarkers, and brought to patients around the
world. Industry members contribute by developing the tools, to select
the best therapies to treat patients: biological investigations of genes
and gene products and algorithms.
“Precision cancer medicine remains very challenging, as the results of
our SHIVA study prove. “ said Prof. Thierry Philip, President of
Institut Curie. “We are thrilled to be able to present SHIVA and debate
about the conclusions we can draw from the study at the WIN annual
symposium on June 28-27 in Paris.”
"What SHIVA tells us is that we
need to continue doing research in this area of personalized medicine,”
said Dr. Richard L.Schilsky Chief Medical Officer of ASCO and chairman
of WIN SAB.
